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0939-4753/ª 2015 Elsevier B.V. All rights reseAbstract Aims: Biologically active phenomena, triggered by atherogenesis and inﬂammation,
lead to aortic valve (AV) calciﬁcation. Lipids play an important role in activating the cell signaling
leading to AV bone deposition. This review, based on evidence from animal and human studies,
mainly focused on the involvement of lipids and atherogenic phenomena in the pathogenesis of
calciﬁc aortic stenosis (AS).
Data synthesis: The role of elevated low density lipoproteins for the risk of both vascular
atherosclerosis and AS has been elucidated. Lipid disorders act synergistically with other risk
factors to increase prevalence of calciﬁc AS. Atherosclerosis is also involved in the pathogenesis
of bone demineralization, a typical hallmark of aging, which is associated with ectopic
calciﬁcation at vascular and valvular levels. Animal studies have recently contributed to
demonstrate that lipids play an important role in AS pathogenesis through the activation of
molecular cell signalings, such as Wnt/Lrp5 and RANK/RANKL/Osteprotegerin, which induce
the transition of valvular myoﬁbroblasts toward an osteogenic phenotype with consequent
valvular bone deposition. Although all these evidence strongly support the lipid theory in AS
pathogenesis, lipids lowering therapies failed to demonstrate in controlled trials a signiﬁcant
efﬁcacy to slow AS progression. Encouraging results from animal studies indicate that physical
activity may counteract the biological processes inducing AV degeneration.
Conclusions: This review indicates a robust interplay between lipids, inﬂammation, and calciﬁc
AS. This new pathophysiological scenario of such an emerging valvular disease paves the way
to the next challenge of cardiovascular research: “prevent and care aortic valve stenosis”.
ª 2015 Elsevier B.V. All rights reserved.di Scienze Mediche Traslazio-
ederico II. Via S. Pansini, 5 e
85; fax: þ39 081 7462339.
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Calciﬁc aortic stenosis (AS) is the most prevalent form of
valvular heart disease in the Western world. Aortic valve
(AV) sclerosis is observed in 75% of people aged more than
85 years, with severe AS reaching a 3% prevalence in the
population over 75 years [1]. New insights in the
pathogenesis of AS have accumulated in recent years. In
fact, AS was previously thought to be the result of a passive,
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Recent in vitro and in vivo studies have instead
demonstrated that atherogenesis and inﬂammation trigger
biologically active and progressive phenomena leading to
valve calciﬁcation and bone deposition [2,3]. At this regard,
it has been found that lipids play an important initiating
role in activating cell signaling leading to valvular calciﬁ-
cation, and oxidized low-density lipoproteins (ox-LDLs)
have been identiﬁed in calciﬁed valves [4]. The hypothesis
that lipids play a role in the development of calciﬁc AS is
further supported by the observation of diffused athero-
sclerotic lesions in the aortic leaﬂets, as well as in coronary
arteries, of patients with familial hypercholesterolemia and
no other traditional atherosclerotic risk factors [5]. A caus-
ative role of elevated LDLs in the risk of both vascular
atherosclerosis and AS has been supported by the Cardio-
vascular Health Study [6] whereas an association between
other studies early, pre-stenotic lesions of AV and increase
(up to 50%) rate of coronary events was also reported, thus
supporting a mechanistic relationship between athero-
sclerosis and valvular and vascular lesions [7,8]. Calciﬁc AS
is also signiﬁcantly associated with increased prevalence of
metabolic syndrome (MS) which is characterized by a
cluster of cardiovascular risk factors including atherogenic
dyslipidemia [9]. Finally, dyslipidemia also seems to be the
link between bone loss and cardiovascular calciﬁcation as
indicated by the observation that patients with lower bone
density and osteoporosis have more severe atherosclerosis
[10e12].
The aims of the present review were: i) to summarize
evidence on the involvement of lipids and atherogenic
phenomena in the pathogenesis of calciﬁc AS gained from
animal and human studies; ii) to identify relationships
between AV disease and other pathologic conditions that
recognize lipid metabolic disorders as common pathoge-
netic mechanisms; iii) to explore the putative molecular
and cellular mechanisms leading to AV calciﬁcation and
evaluate potential links with other biological phenomena
that characterize vascular atherosclerosis and altered bone
turnover; iv) to review the current controversies regarding
the efﬁcaciousness of lipid lowering therapies to slow AS
progression; v) to report the results of experimental
studies testing the efﬁcacy of physical training in AS pri-
mary prevention.
Role of lipids in the pathogenesis of aortic stenosis:
experimental and clinical evidence
Experimental studies in mice have demonstrated that
increased cholesterol levels after an high cholesterol diet
enhance oxidative state in the AV endothelium associated
with increased levels of Ox-LDL and abundant inﬂamma-
tory cell inﬁltrates, containing mast cells, macrophage and
T lymphocytes [13]. Accordingly, himmunoistochemical
studies of human stenotic AV described the presence of
oxidized LDLs, T-cells and macrophages in the sub-
endothelial layer of the ﬁbrosa and close to calcium
accumulation [4,14]. These histological evidence raised the
hypothesis that the combination of extracellular oxidizedlipids and matrix vesicles released from aortic valve
myoﬁbroblasts might represent nuclei for subsequent
calcium deposition and calcium nodules formation.
In vitro studies, showing that oxidized LDLs strongly pro-
mote mineralization when assessed in isolated AV inter-
stitial cells [15], further supported the role of lipids
oxidation as a crucial step in the pathogenesis of AV
calciﬁcation. It has also been demonstrated that the small
dense LDLs, that have greater ability to inﬁltrate tissues
and are prone to the oxidation process, were the only lipid
fraction associated with the accumulation of ox-LDL in the
AV are the small, dense LDL that [16]. In this vein, the high
proportion of small, dense LDLs in patients with MS [9]
might explain the faster progression rate of AS in this
group of patients [9]. The clinical association between LDLs
and AS has been recently evaluated in 6942 patients of the
Cohorts for Heart and Aging Research in Genomic Epide-
miology (CHARGE) Consortium [17]. In this study, genetic
elevation in LDL-C, but not in HDL-C or triglycerides, was
associated with increased prevalence of AV calcium and
incident AS at a follow-up of 15 years. Yet, the role of HDL
in AS remains controversial, since, due to their anti-
atherogenic and anti-inﬂammatory properties, a protective
role in AS pathogenesis and progression would be ex-
pected. In this regard, an high total cholesterol/HDL ratio
and low serum HDL-cholesterol levels have been found to
be associated with a rapid rate of AS progression [18].
Furthermore, the amount of valvular HDL is reduced in
human stenotic AV [19]. Besides to the recognized effect on
LDL-oxidation reduction, increased expression of adhesion
molecules, increased nitric oxide production, and inhibi-
tion of apoptosis represent additional potential protective
mechanisms of HDL on AV degeneration [20,21]. Yet, other
evidence suggest that HDL might promote AS. In fact, in
explanted stenotic human AV, apolipoprotein A1 of HDL
has been found close to calciﬁc nodules and contributes to
the production of amyloid proteins which promote the
transition of isolated valvular interstitial cells (VICs) to-
ward an osteoblast phenotype [22]. Studies conducted on
hypercholesterolemic rabbits showed that infusion of
apoA-I mimetic could favorably affect AS progression in
terms of valve area and leaﬂets thickness [23]. It has been
hypothesized that HDLs might be retained and modiﬁed in
AV, thus promoting lipid retention and contributing to
trigger mineralization by being transformed into amyloid
substance.
AS and altered bone turnover: the role of lipids
It has been shown that mature lamellar bone formation
occurring in calciﬁed human AV presents similarities to
osteoblastogenesis during skeletal bone formation [3].
Histological and immunohistochemical studies have
demonstrated that stenotic AV expresses osteopontin,
bone sialoprotein, osteocalcin, alkaline phosphatase, and
the osteoblast-speciﬁc transcription factor core-binding
factor alpha 1 (Cbfa1) [3]. Skeletal bone osteogenesis in-
volves the differentiation of mesenchymal cells into pre-
osteoblasts and osteoblasts with consequent synthesis
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in the AV the calciﬁcation process starts with the transition
of VICs to a myoﬁbroblast and osteoblast phenotypes and
deposition of mineralized extracellular matrix [3,26e28].
Noteworthy, there are evidence that bone deposition
within the AV is inversely correlated with bone minerali-
zation [29]. This phenomenon has been observed in oste-
oporosis, in patients with chronic kidney disease (CKD)
[30] and in less frequent bone disorders such as Paget’s
disease [31]. The relationship between ectopic calciﬁcation
and reduced bone mineral density is commonly deﬁned as
“bone paradox” [32,33]. This phenomenon has been
largely demonstrated for vascular calciﬁcation and several
evidence indicate that it could be also involved in the
progression of AS [34,35]. In a recent experimental study
conducted in apoE/ mice, a murine model of athero-
sclerosis, an association between AV calciﬁcation, arterial
calciﬁcation and bone mineral loss has been demonstrated
[36]. The authors also demonstrated that a systemic
proinﬂammatory status contributed simultaneously to
bone demineralization and cardiovascular calciﬁcation.
Evidence from this study add new insights in the patho-
genesis of calciﬁc AS, indicating that inﬂammation and
atherosclerosis could represent both the initiating process
and the link between valvular calciﬁcation and altered
bone metabolism [36]. Interestingly, the described asso-
ciation between atherosclerosis, inﬂammation and ectopic
calciﬁcation/bone demineralization seems to be enhanced
in the presence of CKD. Hjortnaes and coll [35], described
increased osteogenic activity in the femurs and greater
arterial and aortic valve osteogenic signal intensity in
apoE/ mice with CKD when compared to animals with
normal renal function. These ﬁndings are in line with the
clinical evidence of bone demineralization and arterial
calciﬁcations in patients with CKD [37].
Role of lipids in the activation of molecular pathways
involved in AV calciﬁcation
The lipoprotein-associated phospholipase A2/LDL/
lysophosphatidylcholine axis
It is widely accepted that enhanced endothelial oxidative
stress promoted by nitric oxide synthase uncoupling,
reactive oxygen species accumulation, and production of
highly reactive lipid-derived oxidized species represent
crucial phenomena leading to AV degeneration and
mineralization [38]. Importantly, ox-LDL are converted
into lysophosphatidylcholine (LPC) by the lipoprotein
associated phospholipase A2 (Lp-PLA2) that is upregulated
in calciﬁed AV [39]. In vitro studies indicate that LPC is a
strong promoter of mineralization in isolated aortic VICs
through a cyclic adenosine monophosphate (cAMP)/pro-
tein kinase A pathway. Lp-PLA2 is produced within the AV
by macrophages and/or is transported in the aortic valve
by LDL, particularly by small, dense LDL. Lipoprotein (a)
represents a vector for oxidized phospholipids transport
into the AV and its plasma levels have been found to be
associated with increased risk of AS [40,41]. Another
molecule involved in the process of lipid retention/modiﬁcation in AV is the phospholipid transfer protein
(PLTP) which is overexpressed in AS valve tissues [42]. It
has also been observed that stimulation of Toll-like re-
ceptor (TLR) 2 promotes the expression of PLTP by VICs
[42]. PLTP binds to HDLs, thus decreasing their ability to
perform reverse cholesterol transport. Stimulation of TLR-
2 and the consequent PLTP overexpression may also be
promoted by biglycan, a proteoglycan, which binds to LDL
particles and induces the retention of lipids in the valve.
Renin-angiotensin system activation in AS
Activation of the renin-angiotensin system (RAS) is also
implicated in AS pathogenesis and RAS inhibition slowers
AS progression [43]. In explanted human stenotic AV,
angiotensin-converting enzyme (ACE) is expressed and
colocalized with angiotensin II [43]. Notably, ACE can be
transported in the aortic valve by LDL, thus promoting
local production of angiotensin II and triggering the pro-
cess of tissue ﬁbrosis which represents an hallmark of AV
remodeling. An intriguing recent hypothesis is that the
presence of ectopic visceral fat might contribute to activate
the RAS system in AV [44], and preliminary data from our
group indicate a strong association between thickness and
inﬂammatory proﬁle of epicardial fat, the visceral fat depot
of the heart, and AS [45].
Wnt/Lrp5 signaling pathway
The upregulation of the Wnt/lipoprotein receptor-related
protein 5 (Lrp5) signaling pathway is considered a relevant
molecular phenomenon that can trigger calciﬁcation
[36,46]. Lipids and other cardiovascular risk factors induce
oxidative stress [38,47] in theAV endotheliumwhich in turn
activates the secretion of cytokines and growth factors
activating cell signaling. Wnt3 secretion from valvular
endothelium and the activation of Wnt canonical pathway
through the Lrp5 are largely dependent on the abnormal
oxidative stress environment promoted by atherosclerosis
[47]. Lrp5 is a member of the family of structurally closely
related cell surface LDLRs (receptors involved in the LDL
metabolism) that have diverse biological functions in
different organs, tissues and cell types [48,49]. The activa-
tion of the canonical Wnt pathway is critical in osteo-
blastogenesis [50]. In the bone, Wnt protein forms a
complexwith a frizzled protein and Lrp5/Lrp6, the so called
Lrp5/Wnt/Frizzled complex [51]. The activation of this
signal leads to an accumulation of b catenin, which controls
the expression of a number of genes including Cbfa1, a key
regulator of genes involved in osteoblastic differentiation.
In the AV, Wnt is secreted from endothelial cells into the
subendothelial space and binds to his receptor on the
myoﬁbroblast extracellular membrane forming the com-
plex Lrp5/Wnt3/Frizzled, which triggers the phenotypic
transition of these cells toward osteoblasts [28]. Figure 1
highlights the molecular mechanisms, at bone and AV
levels, probably involved in the “bone paradox”
phenomenon.
It has been demonstrated that bone matrix protein
expression in the AV is regulated by the Lrp5 pathway in
the presence of hypercholesterolemia. Development of AS
Figure 1 Cell signaling events involved in both bone remodeling and calciﬁc AS. Bone: the activation of Wnt/Lrp5 pathway leads to the differ-
entiation of interstitial cells into mature osteoblasts. Osteoblasts production of OPG and RANK-L modulates osteoclasts activity. In particular, binding
of RANK-L to RANK receptor produces osteoclast differentiation and consequent bone resorption. Importantly, T-cell recruitment signiﬁcantly
contributes to RANKL production and bone resorption. Valve: Wnt/Lrp5 pathway and RANK-L, produced by recruited inﬂammatory cells, both
regulate myoﬁbroblast differentiation into osteoblast-like cells with consequent bone deposition.
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diet [13]. Cholesterol treated eNOS mice developed severe
AS associated with an increase of Wnt3a, Lrp5, Cbfa1 levels
in the valve [13]. These evidence suggest that the osteo-
blast differentiation process may be mediated by the Wnt/
Lrp5 pathway and that hypercholesterolemia and oxida-
tive stress may play a main role in initiating this event.
Osteoprotegerin (OPG)/RANKL/RANK
OPG/RANKL/RANK represents another signaling pathway
potentially involved in AV calciﬁcation. The role of this
signaling in the regulation of bone mass and bone turn-
over has been widely described. RANKL/RANK and osteo-
protegerin are regulators of osteoclast development and
function [52]. RANKL is a cytokine, member of the TNF
ligand superfamily, produced by activated T lymphocytes
and osteoblasts [52]. RANKL binds to its receptor RANK,
which is expressed on osteoclasts and provides the signal
to drive their differentiation from progenitor cells to
mature osteoclasts [52].
Osteoprotegerin (OPG) is a cytokine member of the
TNFa superfamily and is produced by osteoblasts. It is as a
decoy receptor for RANKL, thus inhibiting osteoclasto-
genesis [53].
OPG/RANKL/RANK pathway is considered to be
involved in vascular and AV calciﬁcation [54]. In addition,
opposite regulation of this pathway in bone and vascula-
ture may explain, at least in part, the calciﬁcation paradox
[32] (Fig. 1). It has been demonstrated that the osteoblastic
transition of AV myoﬁbroblasts may be promoted byRANKL, produced by lymphocytes and macrophages [55].
In calciﬁed AV, RANKL expression is highly increased while
OPG expression is not detectable with the net result of a
decrease of the calciﬁcation inhibition potentially associ-
ated with OPG [55]. Furthermore, in cultured AV myoﬁ-
broblasts, exogenous RANKL accelerates the transition
toward an osteogenic phenotype. The antagonistic role of
OPG on the pro-osteogenic stimuli provided by RANKL is
also well established. Exogenous OPG attenuates impair-
ment of AV function in stenosis-prone hypercholesterol-
emic Ldlr/ Apob100/100 mice [56], with signiﬁcant
reduction of valve calciﬁcation. It has been demonstrated
that OPG may also decrease monocyte inﬁltration into
hypercholesterolemic valves by signiﬁcantly reducing
expression of monocyte chemo-attractant protein-1 in
valve tissue [56]. In presence of oxidized lipids, T-lym-
phocytes enhance RANKL production both in AV and
skeletal bone [57,58].
Comprehensively, these data point to common molec-
ular pathways that characterizes vascular and valvular
atherosclerosis as well as bone resorption.
Statin therapy in AS: lights and shadows
In the last years, several studies explored the effects of
targeted medical therapies in slowing AS progression.
Several experimental studies demonstrated that statins
can block the signaling pathways responsible for bone
deposition in the valve leaﬂets [37,59]. In particular, recent
in vitro studies from Rajamannan et al. [13] showed that
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AV endothelial cells and increases eNOS functional enzy-
matic activity. Furthermore, statins reduced Wnt secretion
from valve endothelium and the consequent activation of
LRP5 pathway [13]. In humans, atorvastatin at a dose of
20 mg per day, reduced plasma levels of OPG, osteopontin
and soluble RANK in patients with aortic sclerosis and mild
AS [60]. A study conducted on a large study population of
4105 patients with aortic sclerosis, who were treated with
ACE-Is/ARBs or statins and followed for a mean of
1078  615 days, demonstrated that statin in the early
phase of AV degeneration signiﬁcantly delayed AS pro-
gression [61] Finally, in the randomized RAAVE study, pa-
tients with asymptomatic moderate to severe AS and
elevated cholesterol levels were treated with rosuvastatin
and followed-up for a mean of 18 months. In this study,
statins signiﬁcantly slowed the primary end points of he-
modynamic AS progression as measured by peak velocity,
aortic valve area, peak gradient, and mean gradient. In
addition, secondary end points, including CRP levels, IL-6,
sCD40L, and serum LDL levels, were all reduced signiﬁ-
cantly in the rosuvastatin-treated patients with moderate
AS [62]. Despite the favorable effects of statins observed in
other studies [63,64], including also patients with severe
AS and independently of cholesterol levels, conﬂicting, and
predominantly negative results, have been reported in
prospective controlled trials that tested statins in patients
with moderate to severe AS. In the Scottish Aortic Stenosis
Lipid Lowering Therapy Impact on Regression (SALTIRE),
high dose atorvastatin was not able to induce regression or
reduce the progression of valve disease [65]. The two
largest and most recent trials, evaluating the effects of
lipid lowering therapy in AS, were the Simvastatin and
Ezetimibe in Aortic Stenosis (SEAS) trial [66] and the Aortic
Stenosis Progression Observation Measuring Effects on
Rosuvastatin (ASTRONOMER) trial [67]. Both studies failed
to demonstrate a signiﬁcant effect of statins on AS pro-
gression. The discrepancy between the conspicuous ben-
eﬁts demonstrated by statin in experimental and patient-
based studies and the neutral results reported in
controlled trials remains to be clariﬁed. It is likely that
differences in study designs, enrollment criteria, statin
medication, timing of therapy, and duration of follow-up
can explain conﬂicting results. In addition, it should be
pointed out that although statins substantially reduce LDL-
cholesterol they have neutral or modest effect on circu-
lating small, dense LDL that is the only lipid fraction
associated with the accumulation of tissue ox-LDL. Finally,
the role of LDL in AS pathogenesis could be mostly relevant
only in the initial stages of the disease and in the early
calciﬁcation and mineralization phase, thus explaining the
favorable results of statin therapy in patients with aortic
sclerosis and mild AS.
Exercise training and calciﬁc AS: experimental
observations in the setting of lipid metabolic disorders
Regular physical exercise training plays an important role in
primary and secondary prevention of atheroscleroticcardiovascular diseases [68]. Exercise improves endothelial
function, attenuates oxidative stress, and has a signiﬁcant
impact on blood lipids and lipoprotein proﬁles [69e72]. All
these factors are known to be involved in AV degeneration
and in AS development. This represented the rationale to
test exercise training to prevent the progression of AV dis-
ease. In LDLR deﬁcient mice, an experimental animal model
which is largely used to mimic human atherosclerosis, a
regular exercise training program prevented the develop-
ment of AV sclerosis [73]. Interestingly, in this study, the
cellular and molecular mechanisms by which exercise
counteracted the processes of AV degeneration were: i)
preservation of the integrity of valvular endothelium; ii)
attenuation of oxidative stress and reduction in ox-LDL; iii)
attenuation of proosteogenic signaling pathways.
Unfortunately, extrapolating the effects of training in
the setting of secondary prevention, there are evidence
indicating that once the process of AV calciﬁcation is
started, exercise fails to prevent AS progression. In fact, a
more recent experimental study, conducted in the same
animal model of LDLR deﬁcient mice, indicate that, once
AV degeneration is consolidated, exercise does no longer
induce the favorable molecular effects described above
and has no more slowing effects on valve calciﬁcation
process [74].
Future perspectives and conclusions
In this review, we have highlighted the robust interplay
between lipids, inﬂammation and calciﬁc AS. Although AV
disease has been deﬁned for several years as a passive age-
related disease, the initiating processes leading to AV
calciﬁcation and obstructive valve disease start early and
generate clinical manifestation only in the more advanced
stages of the disease. This probably explains the difﬁculties
to adopt adequate preventive strategies programmes to
counteract such an emerging cardiovascular condition. The
better understanding of the molecular mechanisms
involved in AV degeneration might signiﬁcantly help to
identify novel therapeutic targets. Of interest, the observa-
tion that AS shares several pathophysiologic mechanisms
not only with vascular atherosclerosis but also with non
cardiovascular comorbidities, such as bone disorders, could
open an intriguing scenario for therapies targeting speciﬁc
molecular signaling pathways, such as RANKL inhibition. In
the next future, prospective controlled trials on more
selected AS study populations will hopefully clarify the
potential beneﬁts of statins. In the last years, several
controlled trials evaluated the efﬁcacy of non statin lipid
lowering therapies on different cardiovascular outcomes
but none was designed to evaluate the effects on AS pro-
gression. While the hypothesis that raising HDLc by niacin
would confer any cardiovascular beneﬁt failed to be
conﬁrmed in the large HPS2-THRIVE trial [75], the results of
ongoing trials on CETP inhibitors will contribute to clarify
the role of HDL on cardiac outcomes and might suggest to
design new studies having AS progression as the main
outcome [76,77]. Accordingly, the favorable results of a
recent trial, evaluating the effects of PCSK9 inhibition in
524 V. Parisi et al.heterozygous familial hypercholesterolemia [78], pave the
way for future evaluations in AS. Finally, an attractive pro-
spective is represented by the introduction of exercise
training inprimarypreventionprogrammes considering the
effect of physical activity in attenuating cellular and mo-
lecular mechanisms leading to bone deposition in the AV.References
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